Ultragenyx Pharmaceutical
Develops and commercializes therapies for serious rare and ultra-rare genetic diseases.
$25.68
After-hours close+0.07 (+0.27%)
At close$25.61(−2.48%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 112.44%Insiders 4.22%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 98.49M · Float 94.61M · 96.1% free float
Institutions13F, as of Jun 30, 2026
328 holders · 110.75M shares · 64 new positions · 181 increased · 98 reduced · 43 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 10.65M | 10.82% | +3.35M | Aug 7, 2026 |
| RTW Investments, LP | 7.80M | 7.92% | +4.15M | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 6.79M | 6.89% | +1.40M | Aug 13, 2026 |
| AQR Capital Management LLC | 6.56M | 6.66% | +1.98M | Aug 14, 2026 |
| State Street Corp | 6.16M | 6.25% | +1.14M | Aug 7, 2026 |
| Vanguard Capital Management LLC | 4.30M | 4.36% | +106.7K | Aug 13, 2026 |
| Two Sigma Investments, LP | 3.62M | 3.68% | +1.42M | Aug 14, 2026 |
| Sands Capital Management, LLC | 3.16M | 3.21% | −56.2K | Aug 13, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| RTW Investments, LP | 7.90% | 7.80M | 13G | Aug 14, 2026 ↗ |
| AQR Capital Management, LLC | 6.66% | 6.56M | 13G | Aug 13, 2026 ↗ |
| State Street Corporation | 6.30% | 6.16M | 13G | Aug 7, 2026 ↗ |
| Vanguard Portfolio Management | 5.50% | 5.41M | 13G | Apr 29, 2026 ↗ |
| Vanguard Capital Management | 5.13% | 5.06M | 13G | Jul 31, 2026 ↗ |
| BlackRock, Inc. | 5.10% | 4.82M | 13G | Apr 24, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Emil D. Kakkis | director, officer: President & CEO | 2.89M | 2.94% | Apr 20, 2026 |
| Thomas Richard Kassberg | officer: CBO & EVP | 264.7K | 0.27% | Mar 4, 2025 |
| Dennis Karl Huang | officer: See Remarks | 147.8K | 0.15% | Apr 20, 2026 |
| John Richard Pinion | officer: See Remarks | 133.1K | 0.14% | Apr 20, 2026 |
| Erik Harris | officer: EVP & Chief Commercial Officer | 118.4K | 0.12% | Apr 20, 2026 |
| Eric Crombez | officer: EVP and Chief Medical Officer | 111.2K | 0.11% | May 6, 2026 |
| Howard Horn | officer: Chief Financial Officer | 96.3K | 0.10% | Aug 4, 2026 |
| Karah Herdman Parschauer | officer: EVP and Chief Legal Officer | 92.6K | 0.09% | Aug 4, 2026 |
| Theodore Alan Huizenga | officer: SVP, Chief Accounting Officer | 68.9K | 0.07% | Apr 24, 2026 |
| Michael Narachi | director | 40.4K | 0.04% | May 18, 2026 |
1 ten-percent owner holds 2.60M shares by Form 4, outside the officers-and-directors figure above · 12 people have not refiled in the last 18 months (1.84M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 3, 2026 | Howard Hornofficer: Chief Financial Officer | Sale | 4,696 | $24.92 | 96,295 |
| Aug 3, 2026 | Karah Herdman Parschauerofficer: EVP and Chief Legal Officer | Sale | 1,900 | $24.92 | 92,562 |
| Jul 1, 2026 | Howard Hornofficer: Chief Financial Officer | Sale | 4,698 | $33.13 | 100,991 |
| Jun 15, 2026 | Karah Herdman Parschauerofficer: EVP and Chief Legal Officer | Sale | 1,899 | $24.62 | 94,462 |
| Jun 15, 2026 | Corazon (Corsee) D. Sandersdirector | Sale | 2,000 | $25.05 | 21,095 |
| Jun 1, 2026 | Howard Hornofficer: Chief Financial Officer | Sale | 4,653 | $23.77 | 105,689 |
| May 18, 2026 | Shehnaaz Sulimandirector | Sale | 5,740 | $25.12 | 27,951 |
| May 5, 2026 | Eric Crombezofficer: EVP and Chief Medical Officer | Sale | 344 | $24.96 | 111,189 |
| May 1, 2026 | Howard Hornofficer: Chief Financial Officer | Sale | 4,683 | $24.90 | 110,342 |
| Apr 1, 2026 | Howard Hornofficer: Chief Financial Officer | Sale | 4,683 | $20.97 | 80,351 |
CongressHouse and Senate disclosures
Not reported.